Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
Type:
Grant
Filed:
November 18, 2003
Date of Patent:
July 19, 2005
Assignee:
Cephalon, Inc.
Inventors:
Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Matthew S. Miller, Rabindranath Tripathy, Jeffry L. Vaught
Abstract: The present invention provides processes for the preparation of modafinil which includes the step of reacting benzhydrylthiol and chloroacetamide.
Abstract: The present invention is directed to novel fused pyrrolocarbazoles and isoindolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.
Abstract: The present invention is directed to novel heterocyclic substituted pyrazolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.
Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
Type:
Grant
Filed:
October 26, 2001
Date of Patent:
December 30, 2003
Assignee:
Cephalon, Inc.
Inventors:
Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Matthew S. Miller, Rabindranath Tripathy, Jeffry L. Vaught
Abstract: A non-aqueous, particle-forming, fused pyrrolocarbazole-containing composition is disclosed. Upon contact with an aqueous medium, the particle-forming composition spontaneously disperses into suspended particles, thereby forming a stable suspension that provides greatly improved bioavailability of orally administered fused pyrrolocarbazole compounds.
Type:
Grant
Filed:
October 27, 2000
Date of Patent:
December 9, 2003
Assignee:
Cephalon, Inc.
Inventors:
David A. Dickason, Piyush R. Patel, Vincent Corvari, Efraim Shek, Joseph L. Herman, Jeffry M. Skell
Abstract: The present invention is directed to novel fused pyrrolocarbazoles and isoindolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.
Abstract: The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.
Type:
Grant
Filed:
May 15, 2001
Date of Patent:
December 10, 2002
Assignee:
Cephalon, Inc.
Inventors:
Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo, Jeffry L. Vaught, Matthew S. Miller
Abstract: Pharmaceutical compositions of modafinil compounds, and pharmaceutical, non-aqueous compositions of modafinil compounds in organic solvents are disclosed, along with their use in the treatment of diseases.
Type:
Grant
Filed:
October 10, 2001
Date of Patent:
December 3, 2002
Assignee:
Cephalon, Inc.
Inventors:
Martin J. Jacobs, Bradley T. McIntyre, Piyush R. Patel
Abstract: Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.
Abstract: The present invention is directed to novel heterocyclic substituted pyrazolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.
Abstract: The present invention is directed to novel fused pyrrolocarbazoles and isoindolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.
Abstract: Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and thus exhibits activity in an area of the brain associated with normal wakefulness functions.
Abstract: Conjugates of a cell targetting molecule and a mutant human carboxypeptidase A enzyme are provided. Suitable targetting molecules include antibodies, hormones, ligands, cytokines, antigens, oligonucleotides and peptidomimetics. Enzymes comprising a mutant human carboxypeptidase A enzyme are also provided.
Type:
Grant
Filed:
May 9, 1996
Date of Patent:
October 31, 2000
Assignee:
Glaxo Wellcome Inc.
Inventors:
Gary Keith Smith, Todd Andrew Blumenkopf, Michael Cory
Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
Type:
Grant
Filed:
October 4, 1996
Date of Patent:
August 3, 1999
Assignee:
Glaxo Wellcome Inc.
Inventors:
Ronald W. Barrett, William J. Dower, Steven E. Cwirla, Sherril S. Johnson, Nicholas C. Wrighton, David J. Duffin, Christopher R. Wagstrom
Abstract: The invention is concerned with novel hypolipidemic compounds of formula (I), with processes and novel intermedites for their preparation, pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as atherosclerosis.
Abstract: Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics.
Type:
Grant
Filed:
December 11, 1996
Date of Patent:
February 9, 1999
Assignee:
Glaxo Group Limited
Inventors:
William J. Dower, Ronald W. Barrett, Steven E. Cwirla, Christian M. Gates, Peter J. Schatz, Palaniappan Balasubramanian, Christopher R. Wagstrom, Richard Wayne Hendren, Randoph B. DePrince, Surekha Podduturi, Qun Yin
Abstract: Pharmaceutical compositions comprising modafinil in the form of particles of defined size. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug.
Type:
Grant
Filed:
April 1, 1999
Date of Patent:
January 15, 2002
Assignee:
Cephalon, Inc.
Inventors:
Peter E. Grebow, Vincent Corvari, David Stong